Kas İskelet Sistemi Ağrılarında Proloterapi Enjeksiyonları

Yıl 2019, GETAT Özel Sayı, 91 - 114, 30.09.2019

İlker Solmaz

https://doi.org/10.34084/bshr.571715

Cited By: 2

Öz

Proloterapi, az
miktarda irritan solüsyonun normal hücre ve doku büyümesini uyarmak amacıyla ağrılı,
hasarlı veya dejenere olmuş tendon ve ligamentlerin yapışma bölgelerine
(entezis) uygulandığı enjeksiyonları içeren rejeneratif bir tedavi yöntemidir.
Bu yöntem kas iskelet sistemi kaynaklı ağrıların tedavisinde 80 yıldan uzun
süredir kullanılmaktadır. Proloterapi’nin kas iskelet sistemi sorunlarında
kullanımı, ağrının ligamentlerdeki zayıflama sonucu ortaya çıkan relaksasyona bağlı
olduğu ve bu ligamentlerin tahriş edici, hücre proliferasyonunu uyarıcı
solüsyonların enjeksiyonları ile güçlendirilebileceği düşüncesine
dayandırılmaktadır.Ligament
relaksasyonu; genel olarak ligament içeriğindeki liflerin dayanıklılığının
bozulduğu durum olarak tanımlanmaktadır. İrritan solüsyonların enjeksiyonları
ile tendon ve ligamentlerde fibroblast hiperplazisi, hücre proliferasyonu,
kollojen lif çapında artış gibi histolojik yapısal değişikliklerin yanısıra
tendon ve ligament gücünde artış da gözlenmektedir. Bu etki, yara iyileşme
mekanizmasının tetiklenmesine bağlı oluşmaktadır.Proloterapi
enjeksiyonlarının eklem ağrıları ve eklem laksitesi, kronik bel ağrısı,
epikondilit, tendinopatiler, aşırı kullanım yaralanmaları gibi kas iskelet
sistemi sorunlarındaki etkinliğini araştıran çalışmaların artması ile birlikte
son dönemde bu rejeneratif tedavi yöntemine ilgi giderek artmaktadır. 

Anahtar Kelimeler

Proloterapi, kas iskelet sistemi ağrısı, tendon, ligament, laksite

Prolotherapy Injections for Musculoskeletal Pain

Öz

Prolotherapy is a regenerative treatment method that involves
injections of small amounts of an irritant solution to the site of painful,
injured or degenerated tendon and ligament insertions (entheses) to promote
growth of normal cells and tissues. It has been used in clinical practice for
more than 80 years to treat various musculoskeletal pain. The use of
prolotherapy in musculoskeletal problems is based on the idea that pain is due
to relaxation caused by attenuation of the ligaments and that these ligaments
can be strengthened by injections of irritating, cell proliferation stimulating
solutions.Ligament relaxation; generally described as a condition in which the
strength of the ligament fibers has become impaired. Histological structural
changes such as fibroblast hyperplasia, cell proliferation, increase in
collagen fiber diameter are observed in tendons and ligaments after injections
of irritant solutions. İn addition to histological changes, increase in tendon
and ligament strenght is also observed. This effect is due to triggering of
wound healing mechanism.

With the increasing
number of studies investigating the efficacy of prolotherapy injections in
musculoskeletal problems such as joint pain and joint laxity, chronic low back
pain, epicondylitis, tendinopathies, and overuse injuries, there is an
increasing interest in this regenerative treatment method.

Anahtar Kelimeler

prolotherapy, musculoskeletal pain, tendon, ligament, laxity

Kaynakça

• 1. Yelland MJ, Glasziou PP, Bogduk N, et al. Prolotherapy injections, saline injections, and exercises for chronic low-back pain: a randomized study. Spine. 2003;29:9-16.
• 2. Hackett, G.S. , Hemwall, G.A. , Montgomery, G.A. Ligament and Tendon Relaxation Treated by Prolotherapy. 5th edition. Oak Park (IL): Gustav A. Hemwall; 1993.
• 3. Schultz L. A treatment for subluxation of the temporomandibular joint. JAMA. 1937;25:1035-7.
• 4. Schultz L. Twenty years’ experience in treating hypermobility of the temporomandibular joints. American Journal of Surgery. Vol. 92, December 1956.
• 5. Loeser JD, Treede RD. The Kyoto protocol of IASP basic pain terminology. Pain 2008;137: 473–7.
• 6. Cailliet R: Soft tissue pain and disability, Philadelphia, FA Davis, 1997
• 7. HACKETT GS. Joint stabilization through induced ligament sclerosis. Ohio State Med J. 1953 Oct;49(10):877-84.
• 8. Liu YK, Tipton CM, Matthes RD, et al: An in situ study of the influence of a sclerosing solution in rabbit medial collateral ligaments and its junctional strength. Connec Tissue Res 1983;11:95– 102)
• 9. Maynard JA, Pedrini VA, Pedrini-Mille A, Romanus B, Ohlerking F. Morphological and biochemical effects of sodium morrhuate on tendons. J Orthop Res.1985;3(2):236-48.
• 10. Klein RG, Dorman TA, Johnson CE. Proliferant injections for low back pain: histologic changes of injected ligaments and objective measurements of lumbar spine mobility before and after treatment. J Neurol Orthop Med Surg 1989;10:141 –144
• 11. Meisenbach, R. O.: Sacro-Iliac Relaxation With Analysis of Eighty-four Cases. Surg., Gynec., & 0bst. 1911;12:411-434
• 12. Mengert, W.F. Referred pelvis pain especially due to sacroiliac relaxation or strain. South. M. J. 1943;36:256–263
• 13. Magnuson, P.B. Differential diagnosis of causes of pain in the lower back accompanied by sciatic pain. Ann. Surg. 1944;119:878–891.
• 14. Newman, P. H.: Sprung back. J. Bone Jt Surg. 1952;34B:30-34.
• 15. O’Connell JEA. Sciatica and the mechanism of the production on the clinical syndrome in protrusions of the intervertebral disc. Br J Surg. 1955;30:315.
• 16. G.S Hackett, M.D. Referred Pain from Low Back Ligament Disability. AMA Arch Surg. 1956;73(5):878-883.
• 17. James R, Kesturu G, Balian G, Chhabra AB. Tendon: biology, biomechanics, repair, growth factors, and evolving treatment options. J Hand Surg Am 2008;33:102-112.
• 18. Deie M, Sakamaki Y, Sumen Y, Urabe Y, Ikuta Y. Anterior knee laxity in young women varies with their menstrual cycle. Int Orthop. 2002;26:154–156.
• 19. Heitz NA. Hormonal changes throughout the menstrual cycle and increased anterior cruciate ligament laxity in females. J Athl Train. 1999;343:144–149.
• 20. Yu WD, Liu SH, Hatch JD, Panossian V, Finerman GA. Effect of estrogen on cellular metabolism of the human anterior cruciate ligament. Clin Orthop Relat Res. 1999;366:229–238.
• 21. Slauterbeck JR, Fuzie SF, Smith MP, et al. The menstrual cycle, sex hormones, and anterior cruciate ligament injury. J Athl Train. 2002;37:275–278.
• 22. Kannus P, Natri A. Etiology and pathophysiology of tendon ruptures in sports. Scand J Med Sci Sports 19977107–112.
• 23. Harvie P, Ostlere SJ, Teh J, McNally EG, Clipsham K, Burston BJ, Pollard TC,Carr AJ. Genetic influences in the aetiology of tears of the rotator cuff.Sibling risk of a full-thickness tear. J Bone Joint Surg Br. 2004 Jul;86(5):696-700.
• 24. Flynn R K, Pedersen C L, Birmingham T B. et al The familial predisposition toward tearing the anterior cruciate ligament: a case control study. Am J Sports Med 20053323–28)
• 25. Child AH. Joint hypermobility syndrome: inherited disorder of collagen synthesis. J Rheumatol 1986; 13: 239 –243.
• 26. Arendt Nielsen L, Svensson P. Referred muscle pain: basic and clinical findings. Clin J Pain. 2001;17: 11–19.
• 27. IASP. IASP Task Force on Taxonomy,. In: Merskey H, Bogduk N, editors. Classification of Chronic Pain. Second edition ed Seattle: IASP Press; 1994. pp. 209–214.
• 28. Longmire DR. The classification of pain and pain syndromes. Pain Digest 1992;2:229-233.
• 29. Józsa L, Kannus P. Histopathological findings in spontaneous tendon ruptures. Scand J Med Sci Sports. 1997 Apr;7(2):113-8.
• 30. Koob TJ, Clark PE, Hernandez DJ, Thurmond FA, Vogel KG. Compression loading in vitro regulates proteoglycans synthesis by tendon fibrocartilage. Arch Biochem Biophys 1992; 298:303-312
• 31. Monaco JL, Lawrence T, Acute Wound Healing: An Overview. J Clin Plastic Surg 2003; 30: 1 – 12
• 32. Hanna JR, Giacopelli JA. A Review of Wound Healing and Wound Dressing Products. J Foot Ankle Surg 1997 ; 36: 2 - 14
• 33. Bujía J, Sittinger M, Wilmes E, Hammer C. Effect of growth factors on cell proliferation by human nasal septal chondrocytes cultured in monolayer. Acta Otolaryngol. 1994 Sep;114(5):539-43.
• 34. Dunham BP, Koch RJ. Basic fibroblast growth factor and insulinlike growth factor I support the growth of human septal chondrocytes in a serum-free environment. Arch Otolaryngol Head Neck Surg. 1998 Dec;124(12):1325-30.
• 35. Van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB. Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation. Osteoarthritis Cartilage. 1998 Sep;6(5):306-17.
• 36. Wakitani S, Imoto K, Kimura T, Ochi T, Matsumoto K, Nakamura T. Hepatocyte growth factor facilitates cartilage repair. Full thickness articular cartilage defect studied in rabbit knees. Acta Orthop Scand. 1997 Oct;68(5):474-80.
• 37. Jensen K, et al. Response of knee ligaments to Prolotherapy in a rat injury model. American Journal of Sports Medicine. 2008;36:1347-1357.
• 38. Jensen K, et al. Early infammatory response of knee ligaments to Prolotherapy in a rat model. Journal of Orthopedic Research. 2008;26:816-823
• 39. Reeves K, et al. Evidenced-based regenerative injection (Prolotherapy) in sports medicine. In Seidenberg P, Beutler A (eds.) The Sports Medicine Resource Manual. 2008; Saunders Publishing, Philadelphia PA, Chapter 50.
• 40. Natarajan R, et al. Vascular smooth muscle cells exhibit increased growth in response to elevated glucose. Biochemistry and Biophysic Research and Communication. 1992;186:552-560.
• 41. McGinn S, et al. High glucose and endothelial cell growth: novel effects independent of autocrine TGF-beta 1 and hyperosmolality. American Journal of Phyiology and Cell Physiology. 2003;234:C1374-C1386.
• 42. Caruccio L, et al. The heat-shock transcription factor HSF1 is rapidly activated by either hyper- or hypo-osmotic stress in mammalian cells. Journal of Biochemistry. 1997;327:341-347.)
• 43. Clarkson MR, Murphy M, Gupta S, Lambe T, Mackenzie HS, Godson C, Martin F, Brady HR. High glucose-altered gene expression in mesangial cells. Actin-regulatory protein gene expression is triggered by oxidative stress and cytoskeletal disassembly. J Biol Chem. 2002 Mar 22;277(12):9707-12.
• 44. Lam S, van der Geest RN, Verhagen NA, van Nieuwenhoven FA, Blom IE, Aten J, Goldschmeding R, Daha MR, van Kooten C. Connective tissue growth factor and igf-I are produced by human renal fibroblasts and cooperate in the induction of collagen production by high glucose. Diabetes. 2003 Dec;52(12):2975-83.
• 45. Di Paloa S, et al. High glucose concentration induces the overexpression of transforming growth factor-beta through the activation of a platelet-derived growth factor loop in human mesangial cells. American Journal of Pathology. 1996;149:2095-2106.
• 46. Fukuda K, et al. High concentration of glucose increases mitogenic responsiveness to heparin-binding epidermal growth factor-like growth factor in rat vascular smooth muscle cells. Arteriosclerosis Thombosis and Vasculature Biology. 1997;17:1962-1968.
• 47. Oh J, et al. Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Kidney International. 1998;54:1872-1878.
• 48. Murphy M, et al. Suppression subtractive hybridization identi es high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. Journal of Biology and Chemistry. 1999;274:5830-5834.)
• 49. Ohgi S, et al. Glucose modulates growth of gingival fibbroblasts and periodontal ligament cells: correlation with expression of basic broblast growth factor. Journal of Periodontal Research. 1996;31:579-588.
• 50. Pugliese G, et al. Increased activity of the insulin-like growth factor system in mesangial cells cultured in high glucose conditions. Relation to glucose-enhanced extracellular matrix production. Diabetologia. 1996;39:775-784.
• 51. Reeves K. Prolotherapy: injection of growth factors or growth factor production stimulants to growth normal cells or tissue. In Waldman SD (ed): Pain Management. Philadelphia, Elsevier, 2006; 1106-1127.
• 52. Kim H, et al. The effects of anti-inflammatory drugs on histologic findings of the experimental Prolotherapy model. Journal of the Korean Academy of Rehabilitation Medicine. 2006;30:378-384.
• 53. Ahn K, et al. The effect of the Prolotherapy on the injured Achilles tendon in a rat model. Journal of the Korean Academy of Rehabilitation Medicine. 2002;26:332-336.
• 54. Oh S, et al. Dextrose-induced subsynovial connective tissue fibrosis in the rabbit carpal tunnel: a protential model to study carpal tunnel syndrome. Hand. 2008;3:34-40.)
• 55. Kim H, et al. Comparison of histological changes in accordance with the level of dextrose-concentration in experimental Prolotherapy model. Journal of Korean Academy of Rehabilitation Medicine. 2003;27:935-940.
• 56. Reinhold D, Ansorge S, Schleicher ED. Elevated glucose levels stimulate transforming growth factor-beta 1 (TGF-beta 1), suppress interleukin IL-2, IL-6 and IL-10 production and DNA synthesis in peripheral blood mononuclear cells. Horm Metab Res 1996;28:267–70.
• 57. Jo, Daehyun, and Myounghee Kim. "The effects of Prolotherapy on knee joint pain due to ligament laxity." Journal of the Korean Pain Society 17.1 (2004): 47-50.
• 58. Hauser RA, Hauser MA. A Retrospective Study on Dextrose Prolotherapy for Unresolved Knee Pain at an Outpatient Charity Clinic in Rural Illinois. Journal of Prolotherapy. 2009;1:11-21.
• 59. Lohmander LS, Ostenberg A, Englund M, and Roos H. High prevalence of knee osteoarthritis, pain and functional limitations in female soccer players twelve years after anterior cruciate ligament injury. Arthritis & Rheumatism. October 2004. 50(10):3142-3152.
• 60. Panush R. Recreational activities and degenerative joint disease. Sports Medicine. January 1994. 17:1-5
• 61. Morehead K and Sack K. Osteoarthritis: What therapies for this disease of many causes? Postgraduate Medicine. November 2003. pp 12-17.
• 62. Rabago D, Patterson JJ, Mundt M, Kijowski R, Grettie J, Segal NA, Zgierska A. Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial. Ann. Fam Med. 2013 May-Jun;11(3):229-37.
• 63. Rabago D, Zgierska A, Fortney L. Hypertonic dextrose injections (Prolotherapy) for knee osteoarthritis: results of a single-arm uncontrolled study with 1-year follow-up.J Altern Complement Med. 2012 Apr;18(4):408-14.)
• 64. Topol GA, Podesta LA, Reeves KD, Giraldo MM, Johnson LL, Grasso R, Jamín A, Clark T, Rabago D. Chondrogenic Effect of Intra-articular Hypertonic-Dextrose (Prolotherapy) in Severe Knee Osteoarthritis. PM R. 2016 Nov;8(11):1072-1082
• 65. Rabago, David, et al. "Hypertonic dextrose injection (prolotherapy) for knee osteoarthritis: Long term outcomes." Complementary therapies in medicine 23.3 (2015): 388-395.
• 66. Rabago D, van Leuven L, Benes L, Fortney L, Slattengren A, Grettie J, Mundt M. Qualitative Assessment of Patients Receiving Prolotherapy for Knee Osteoarthritis in a Multimethod Study. J Altern Complement Med. 2016 Dec;22(12):983-989.
• 67. Eslamian F, Amouzandeh B. Therapeutic effects of prolotherapy with intra-articular dextrose injection in patients with moderate knee osteoarthritis: a single-arm study with 6 months follow up. Ther Adv Musculoskelet Dis. 2015 Apr;7(2):35-44.
• 68. Hassan F, Trebinjac S, Murrell WD, Maffulli N. The effectiveness of prolotherapy in treating knee osteoarthritis in adults: a systematic review. British medical bulletin. 2017 Mar 4;122(1):91-108.
• 69. Sit, Regina WS, et al. "Hypertonic dextrose injections (prolotherapy) in the treatment of symptomatic knee osteoarthritis: a systematic review and meta-analysis." Scientific reports 6 (2016): 25247.
• 70. Kim, Jong Moon. "The Effect of Prolotherapy for Osteoarthritis of the Knee." Journal of the Korean Academy of Rehabilitation Medicine 26.4 (2002): 445-448.
• 71. Reeves, Kenneth D., and Khatab Hassanein. "Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity." Alternative therapies in health and medicine 6.2 (2000): 68-80.
• 72. Lohmander LS, et al. The long-term consequences of anterior cruciate ligament and meniscal injuries: osteoarthritis. American Journal of Sports Medicine. 2007;35:1756-1769.
• 73. Bhargava MM, et al. The effect of cytokines on the proliferation and migration of bovine meniscal cells. The American Journal of Sports Medicine. 1999;27:636-643.
• 74. Spindler KP, et al. Regional mitogenic response of the meniscus to platelet-derived growth factor (PDGF-AB). Journal of Orthopaedic Research. 2005;13:201-207.
• 75. Murray MM, et al. Enhanced histologic repair in a central wound in the anterior cruciate ligament with a collagen-platelet-rich plasma scaffold. Journal of Orthopedic Research. & Hashimoto J, et al. Meniscal repair using fibrin sealant and endothelial growth factor. The American Journal of Sports Medicine. 1992;20:537-541.
• 76. Reeves KD. Technique of Prolotherapy. In Lennard T. Physiatric Procedures in Clinical Practice. Philadelphia, PA: Hanely & Belfus; 1995. p. 57-70.
• 77. Reeves KD. Prolotherapy: Basic Science, Clinical Studies, and Technique. In Lennard, T. Pain Procedures in Clinical Practice, Second Edition. Philadelphia, PA: Hanley & Belfus; 2000. p. 172-190.
• 78. Okuda Y, et al. Increased production of PDGH by angiotensin and high glucose in human vascular endothelium. Life Sciences. 1996;59:455-461.
• 79. Kolm-Litty V, et al. High glucose-induced transforming growth factor beta 1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. Journal of Clinical Investigation. 1998;101:160-169.
• 80. Liu X, et al. High glucose upregulates connective tissue growth factor expression in human vascular smooth muscle cells. BMC Cell Biology. 2007;8:1-14.)
• 81. Hauser R. A Retrospective Study Shows Prolotherapy is Effective in the Treatment of MRI-Documented Meniscal Tears and Degeneration. Journal of Prolotherap. 2010;2(3):416-437
• 82. Reeves KD and Hassanein K. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Alternative Therapies. March 2000. 6(2):68-80.
• 83. Reeves, K. Dean, and Khatab M. Hassanein. "Long-term effects of dextrose prolotherapy for anterior cruciate ligament laxity." Alternative therapies in health and medicine 9.3 (2003): 58-63.
• 84. Kırdemir Vecihi, Aslan A. Ankle Ligament injuries. Turkiye Klinikleri J Surg Med Sci 2007;3(39):22-7
• 85. Tsatsos G, Mandal R. Prolotherapy in the treatment of foot problems. J Am Podiatr Med Assoc 2002;92:366-8.
• 86. Hauser RA, Hauser MA, Cukla J. Dextrose Prolotherapy injections for chronic ankle pain. Pract Pain Manag 2010: 70-76.
• 87. Rivello Gj. McGlamry's Comprehensive Textbook of Foot & Ankle Surgery 4th Edition. Chapter 35, 181-86
• 88. Yelland MJ, et al. Prolotherapy injections and eccentric loading exercises for painful Achilles tendinosis: a randomised trial. Br J Sports Med 2011;45:421-8.
• 89. Maxwell NJ, Ryan MB, Taunton JE, et al. Sonographically guided intratendinous injection of hyperosmolar dextrose to treat chronic tendinosis of the Achilles tendon: a pilot study. AJR Am J Roentgenol 2007;189:W215-20.
• 90. Lyftogt J. Prolotherapy and Achilles tendinopathy: a prospective pilot study of an old treatment. Australasian Musculoskeletal Medicine. 2005;16–19
• 91. Ryan M, Wong A, Taunton J. Favorable outcomes after sonographically guided intratendinous injection of hyperosmolar dextrose for chronic insertional and midportion achilles tendinosis. AJR Am J Roentgenol 2010;194:1047-53.
• 92. Ersen Ö, Koca K. A randomized-controlled trial of prolotherapy injections in the treatment of plantar fasciitis. Turk J Phys Med Rehab 2018;64(1):59-65.
• 93. Ryan MB, Wong AD, Gillies JH, Wong J, Taunton JE. Sonographically guided intratendinous injections of hyperosmolar dextrose/lidocaine: a pilot study for the treatment of chronic plantar fasciitis. Br J Sports Med. 2009 Apr;43(4):303-6
• 94. Kurtz S. Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg Am. 2005 Jul;87(7):1487-97
• 95. Kim S. Changes in surgical loads and economic burden of hip and knee replacements in the US: 1997-2004. Arthritis Rheum. 2008 Apr 15;59(4):481-8.
• 96. Agency for Healthcare Research and Quality (AHRQ). Agency News and Notes: Musculoskeletal procedures account for over 10 percent of all hospital care in the United States.
• 97. Freedman KB. A meta-analysis of thromboembolic prophylaxis for elective total hip arthroplasty. Paper presented at: Ninth Annual Meeting of the American Association of Hip and Knee Surgeons; November 12-14,1999; Dallas, Texas.
• 98. Elfick A. Variation in the wear rate during the life of a total hip arthroplasty: A simulator and retrieval study. J Arthroplasty. 2000;379:34-40.
• 99. Alternative treatments: Dealing with chronic pain. Mayo Clinic Health Letter. April 2005. 23(4)
• 100. Lennard T. Pain Procedures in Clinical Practice. 2nd ed. Philadelphia, PA: Hanley & Belfus, Inc.;2000.
• 101. Cyrus Cooper, Hazel Inskip; Individual Risk factors for Hip Osteoarthritis: Obesity, Hip Injury and Physical Activity, American Journal of Epidemiology, Volume 147, Issue 6, 15 March 1998, 516–52
• 102. Hauser A, Orlofsky A. Regenerative Injection Therapy (Prolotherapy) for Hip Labrum Lesions:Rationale and Retrospective Study. The Open Rehabilitation Journal, 2013, 6, 59-68
• 103. JW, Norbury. Diagnosis and Management of priformis syndrome. Practical Neurology May 2012.
• 104. Holmich P, Uhrskou P, Ulnits L, et al. Effectiveness of active physical training as treatment for long-standing adductor-related groin pain in athletes; randomized trial. Lancet 1999;353:439-43.
• 105. Topol GA, Reeves KD, Hassanein KM. Efficacy of dextrose prolotherapy in elite male kicking-sport athletes with chronic groin pain. Arch Phys Med Rehabil 2005;86:697–702.
• 106. Hauser A. A Retrospective Study on Hackett-Hemwall Dextrose Prolotherapy for Chronic Hip Pain at an Outpatient Charity Clinic in Rural Illinois. Journal of Prolotherapy. 2009;2:76-88.
• 107. Ongley MJ, Klein RG, Dorman TA, Eck BC. A new approach to the treatment of chronic low back pain. Lancet 1987;2:143–146
• 108. Robert G. Schwartz, M.D. and Noreen Sagedy, M.D. Prolotherapy: A Literature Review and Retrospective Study. The Journal of Neurological and Orthopadic Medicine and Surgery, Vol. 12. No. 3. 1991
• 109. Seven MM, Ersen O, Akpancar S, Ozkan H, Turkkan S, Yıldız Y, Koca K. Effectiveness of prolotherapy in the treatment of chronic rotator cuff lesions.Orthop Traumatol Surg Res. 2017 May;103(3):427-433
• 110. Koca K, Kürklü M. Karpal instabilitelerin radyolojik değerlendirilmesi. TOTBİD Dergisi 2013;12(1):47-53
• 111. Pilný J, Svarc A, Hoza P, Vodicka Z, Krbec M. [Arthritis development following untreated scapholunate instability of the wrist]. Acta Chir Orthop Traumatol Cech. 2010 Apr;77(2):131-3.
• 112. Hauser R, Hauser M, Holian P. Dextrose prolotherapy for unresolved wrist pain. Practical Pain Management. 2009;Nov/Dec:72-79
• 113. O’Connor F. Managing overuse injuries. A sys- tematic approach. The Physician and Sports Medi- cine. 1997. 25: 88-113.
• 114. Pecar D and Avdic D. Efficacy of tennis elbow (Epicondylitis humeri radialis) treatment in CBR “Praxis.” Bosn J Med Sci. Feb 2009. 9(1): 25-30
• 115. Pecar D and Avdic D. Efficacy of tennis elbow (Epicondylitis humeri radialis) treatment in CBR “Praxis.” Bosn J Med Sci. Feb 2009. 9(1): 25-30
• 116. Alternative treatments: Dealing with chronic pain. Mayo Clinic Health Letter. April 2005. 23(4).
• 117. Lennard, T. Pain Procedures in Clinical Practice. Second Edition. Hanley & Belfus, Inc. Philadelphia, PA. 2000.
• 118. Hauser R, Hauser M, Holian P. Dextrose prolotherapy for unresolved wrist pain. Practical Pain Management. 2009;Nov/Dec:72-79.
• 119. Jobe F, Ciccotti M. Lateral and medial epicondylitis of the elbow. J Am Acad Orthop Surg 1994;2:1-8.
• 120. Allman F, Nirschl R, Plagenhoef S, et al. Tennis elbow: Who’s most likely to get it and how. Physician Sports Med 1975;3:43-58.
• 121. Leach R, Miller J. Lateral and medial epicondylitis of the elbow. Clin Sports Med 1987;6:59-72.
• 122. Nirschl R. Soft tissue injuries about the elbow. Clin Sports Med 1985; 5:637-652.
• 123. Carayannopoulos A, Borg-Stein J, Sokolof J, Meleger A, Rosenberg D. Prolotherapy versus corticosteroid injections for the treatment of lateral epicondylosis: a randomized controlled trial. PM R. 2011 Aug;3(8):706-15
• 124. Scarpone M, Rabago D, Arbogest J, Snell E, Zgierska A. The efficacy of prolotherapy for lateral epicondylosis: A pilot study. Clin J Sports Med 2008;18:248-254.
• 125. Shin J, Seo K-M, Kim D-K, Kim B-K, Kang S-H. The effect of prolotherapy on lateral epicondylitis of elbow. J Korean Acad Rehabil Med. 2002;26:764–8.